

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Volume 53

July 2009

No. 7

CHEMISTRY; BIOSYNTHESIS

- Plant Agricultural Streptomycin Formulations Do Not Carry Antibiotic Resistance Genes** Fabio Rezzonico, Virginia O. Stockwell, and Brion Duffy 3173–3177

MECHANISMS OF ACTION: PHYSIOLOGICAL EFFECTS

- Novel Anion Liposome-Encapsulated Antisense Oligonucleotide Restores Susceptibility of Methicillin-Resistant *Staphylococcus aureus* and Rescues Mice from Lethal Sepsis by Targeting *mecA*** Jingru Meng, Hui Wang, Zheng Hou, Tao Chen, Jingguo Fu, Xue Ma, Gonghao He, Xiaoyan Xue, Min Jia, and Xiaoxing Luo 2871–2878
- Substrate-Induced Inactivation of the *Escherichia coli* AmiD N-Acetylmuramoyl-L-Alanine Amidase Highlights a New Strategy To Inhibit This Class of Enzyme** Anne Pennartz, Catherine Génèreux, Claudine Parquet, Dominique Mengin-Lecreux, and Bernard Joris 2991–2997
- Hypersusceptibility to Azole Antifungals in a Clinical Isolate of *Candida glabrata* with Reduced Aerobic Growth** Patrick Vandeputte, Guy Tronchin, Françoise Rocher, Gilles Renier, Thierry Bergès, Dominique Chabasse, and Jean-Philippe Bouchara 3034–3041
- Crystal Structure of *Bacillus anthracis* Dihydrofolate Reductase with the Dihydrophthalazine-Based Trimethoprim Derivative RAB1 Provides a Structural Explanation of Potency and Selectivity** Christina R. Bourne, Richard A. Bunce, Philip C. Bourne, K. Darrell Berlin, Esther W. Barrow, and William W. Barrow 3065–3073
- Lon Protease Is Essential for Paradoxical Survival of *Escherichia coli* Exposed to High Concentrations of Quinolone** Muhammad Malik, Joseph Capecci, and Karl Drlica 3103–3105

MECHANISMS OF RESISTANCE

- Effect of MexXY Overexpression on Ceftobiprole Susceptibility in *Pseudomonas aeruginosa*** Ellen Z. Baum, Steven M. Crespo-Carbone, Brian J. Morrow, Todd A. Davies, Barbara D. Foleno, Wenping He, Anne Marie Queenan, and Karen Bush 2785–2790
- Heteroresistance to Fluconazole in *Cryptococcus neoformans* Is Intrinsic and Associated with Virulence** Edward Sionov, Yun C. Chang, H. Martin Garraffo, and Kyung J. Kwon-Chung 2804–2815
- Noncanonical Vancomycin Resistance Cluster from *Desulfitobacterium hafniense* Y51** Lindsay Kalan, Sara Ebert, Tom Kelly, and Gerard D. Wright 2841–2845
- Molecular Characteristics of Extended-Spectrum- β -Lactamase-Producing *Escherichia coli* Isolates Causing Bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of Clone ST131 as a Cause of Community-Acquired Infections** Johann D. D. Pitout, Daniel B. Gregson, Lorraine Campbell, and Kevin B. Laupland 2846–2851
- AmpD₁ Is Involved in Expression of the Chromosomal L1 and L2 β -Lactamases of *Stenotrophomonas maltophilia*** Tsuey-Ching Yang, Yi-Wei Huang, Rouh-Mei Hu, Shao-Cheng Huang, and Yu-Tzu Lin 2902–2907
- Secretion of GOB Metallo- β -Lactamase in *Escherichia coli* Depends Strictly on the Cooperation between the Cytoplasmic DnaK Chaperone System and the Sec Machinery: Completion of Folding and Zn(II) Ion Acquisition Occur in the Bacterial Periplasm** Jorgelina Morán-Barrio, Adriana S. Limansky, and Alejandro M. Viale 2908–2917

Continued on following page

Nonsense and Missense Mutations in <i>FCY2</i> and <i>FCY1</i> Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of <i>Candida lusitanae</i>	Martine Florent, Thierry Noël, Gwenaël Ruprich-Robert, Bruno Da Silva, Valérie Fitton-Ouhabi, Christiane Chastin, Nicolas Papon, and Florence Chapeland-Leclerc	2982–2990
Genetic and Biochemical Characterization of the First Extended-Spectrum CARB-Type β-Lactamase, RTG-4, from <i>Acinetobacter baumannii</i>	Anaïs Potron, Laurent Poiriel, Jacques Croizé, Vanessa Chantepedrix, and Patrice Nordmann	3010–3016
Structural Basis of APH(3')-IIIa-Mediated Resistance to N1-Substituted Aminoglycoside Antibiotics	Desiree H. Fong and Albert M. Berghuis	3049–3055
First Report of Plasmid-Mediated Quinolone Resistance Determinant <i>qnrS1</i> in an <i>Escherichia coli</i> Strain of Animal Origin in Italy	Marina Cerquetti, Aurora García-Fernández, Maria Giufrè, Daniela Fortini, Marisa Accogli, Caterina Graziani, Ida Luzzi, Alfredo Caprioli, and Alessandra Carattoli	3112–3114
Characterization of Cefoxitin-Resistant <i>Escherichia coli</i> Isolates from Recreational Beaches and Private Drinking Water in Canada between 2004 and 2006	L. F. Mataseje, N. Neumann, B. Crago, P. Baudry, G. G. Zhanel, M. Louie, M. R. Mulvey, and the ARO Water Study Group	3126–3130
Carriage of CTX-M-15-Producing <i>Escherichia coli</i> Isolates among Children Living in a Remote Village in Senegal	Etienne Ruppé, Paul-Louis Woerther, Abdoulaye Diop, Anne-Marie Sene, Annaelle Da Costa, Guillaume Arlet, Antoine Andreumont, and Bernard Rouveix	3135–3137
First Detection of Plasmid-Encoded <i>bla</i>_{OXY} β-Lactamase	J. J. González-López, A. Coelho, M. N. Larrosa, S. Lavilla, R. Bartolomé, and G. Prats	3143–3146
Emergence of Quinolone-Resistant <i>Bordetella pertussis</i> in Japan	Masayuki Ohtsuka, Ken Kikuchi, Kenichiro Shimizu, Namiko Takahashi, Yuka Ono, Takashi Sasaki, and Keiichi Hiramatsu	3147–3149
Reduced Susceptibility to Cefepime among <i>Escherichia coli</i> Clinical Isolates Producing Novel Variants of CMY-2 β-Lactamase	Yohei Doi, David L. Paterson, Jennifer M. Adams-Haduch, Hanna E. Sidjabat, Alexandra O'Keefe, Andrea Endimiani, and Robert A. Bonomo	3159–3161
Prevalence of Fluoroquinolone Resistance among Tuberculosis Patients in Shanghai, China	Peng Xu, Xia Li, Ming Zhao, Xiaohong Gui, Kathryn DeRiemer, Sebastien Gagneux, Jian Mei, and Qian Gao	3170–3172
SUSCEPTIBILITY		
Epidemic Clonal Groups of <i>Escherichia coli</i> as a Cause of Antimicrobial-Resistant Urinary Tract Infections in Canada, 2002 to 2004	James R. Johnson, Megan Menard, Brian Johnston, Michael A. Kuskowski, Kim Nichol, and George G. Zhanel	2733–2739
Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity	Georgina A. Holloway, William N. Charman, Alan H. Fairlamb, Reto Brun, Marcel Kaiser, Edmund Kostewicz, Patrizia M. Novello, John P. Parisot, John Richardson, Ian P. Street, Keith G. Watson, and Jonathan B. Baell	2824–2833

Sitafloxacin Activity against <i>Helicobacter pylori</i> Isolates, Including Those with <i>gyrA</i> Mutations	Kazunari Murakami, Tadayoshi Okimoto, Masaaki Kodama, Jin Tanahashi, Toshio Fujioka, Fumiaki Ikeda, Hiroe Muraoka, Motoko Takigawa, Takeshi Saika, Miyuki Hasegawa, and Intetsu Kobayashi	3097–3099
In Vitro Activities of Echinocandins against <i>Candida krusei</i> Determined by Three Methods: MIC and Minimal Fungicidal Concentration Measurements and Time-Kill Studies	Emilia Cantón, Javier Pemán, Amparo Valentín, Ana Espinel-Ingroff, and Miguel Gobernado	3108–3111
In Vitro Activity of Doripenem against <i>Burkholderia pseudomallei</i>	Visanu Thamlikitkul and Suwanna Trakulsomboon	3115–3117
Resistance Selection Studies Comparing the Activity of Razupenem (PTZ601) to Vancomycin and Linezolid against Eight Methicillin-Resistant and Two Methicillin-Susceptible <i>Staphylococcus aureus</i> Strains	Catherine Clark, Klaudia Kosowska-Shick, Pamela McGhee, Bonifacio Dewasse, Linda Beachel, and Peter C. Appelbaum	3118–3121
In Vitro Chemosensitization of <i>Plasmodium falciparum</i> to Antimalarials by Verapamil and Probenecid	Victor Masseno, Steven Muriithi, and Alexis Nzila	3131–3134
Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i>	Helio S. Sader, Paul R. Rhomberg, and Ronald N. Jones	3162–3165
In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing <i>Staphylococcus aureus</i>, <i>S. epidermidis</i>, and <i>Enterococcus faecalis</i> Strains	Kerry L. LaPlante and Leonard A. Mermel	3166–3169
ANALYTICAL PROCEDURES		
Simultaneous Determination of Voriconazole and Posaconazole Concentrations in Human Plasma by High-Performance Liquid Chromatography	Kathrin Kahle, Peter Langmann, Diana Schirmer, Ulrike Lenker, Daniela Keller, Annegret Helle, Hartwig Klinker, and Werner J. Heinz	3140–3142
ANTIVIRAL AGENTS		
Novel Antiviral Agent DTriP-22 Targets RNA-Dependent RNA Polymerase of Enterovirus 71	Tzu-Chun Chen, Hwan-You Chang, Pei-Fen Lin, Jyh-Haur Chern, John Tsu-An Hsu, Chu-Yi Chang, and Shin-Ru Shih	2740–2747
Mitochondrial DNA Depletion in Rat Liver Induced by Fosaltudine Tidoxil, a Novel Nucleoside Reverse Transcriptase Inhibitor Prodrug	Ana C. Venhoff, Dirk Lebrecht, Frank U. Reuss, Brigitte Heckl-Östreicher, Roland Wehr, Ulrich A. Walker, and Nils Venhoff	2748–2751
Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates	Jie Fang, Michael J. Wichroski, Steven M. Levine, Carl J. Baldick, Charles E. Mazzucco, Ann W. Walsh, Bernadette K. Kienzle, Ronald E. Rose, Kevin A. Pokornowski, Richard J. Colonno, and Daniel J. Tenney	2762–2772
GS-9191 Is a Novel Topical Prodrug of the Nucleotide Analog 9-(2-Phosphonylmethoxyethyl)Guanine with Antiproliferative Activity and Possible Utility in the Treatment of Human Papillomavirus Lesions	Grushenka H. I. Wolfgang, Riri Shibata, Jianying Wang, Adrian S. Ray, Sylvia Wu, Edward Doerrfler, Hans Reiser, William A. Lee, Gabriel Birkus, Neil D. Christensen, Graciela Andrei, and Robert Snoeck	2777–2784

Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the Human Immunodeficiency Virus Type 1 Regulatory Protein Rev	Valentina Svicher, Claudia Alteri, Roberta D'Arrigo, Alessandro Laganà, Maria Trignetti, Sergio Lo Caputo, Anna Paola Callegaro, Franco Maggiolo, Francesco Mazzotta, Alfredo Ferro, Salvatore Dimonte, Stefano Aquaro, Giovanni di Perri, Stefano Bonora, Chiara Tommasi, Maria Paola Trotta, Pasquale Narciso, Andrea Antinori, Carlo Federico Perno, and Francesca Ceccherini-Silberstein	2816–2823
Alkoxyalkyl Esters of 9-(S)-(3-Hydroxy-2-Phosphonomethoxypropyl)Adenine Are Potent and Selective Inhibitors of Hepatitis B Virus (HBV) Replication In Vitro and in HBV Transgenic Mice In Vivo	John D. Morrey, Brent E. Korba, James R. Beadle, David L. Wyles, and Karl Y. Hostetler	2865–2870
Population Pharmacokinetics of Acyclovir in Children and Young People with Malignancy after Administration of Intravenous Acyclovir or Oral Valacyclovir	L. Zeng, C. E. Nath, E. Y. L. Blair, P. J. Shaw, K. Stephen, J. W. Earl, J. C. Coakley, and A. J. McLachlan	2918–2927
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy	Constance Delaugerre, Philippe Flandre, Marie Laure Chaix, Jade Ghosn, François Raffi, Pierre Dellamonica, H. Jaeger, D. Shürmann, Isabelle Cohen-Codar, Philippe Ngo Van, Michael Norton, Anne-Marie Taburet, Jean-François Delfraissy, Christine Rouzioux, and for the MONARK Study Group	2934–2939
The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100	Tsutomu Murakami, Sei Kumakura, Toru Yamazaki, Reiko Tanaka, Makiko Hamatake, Kazu Okuma, Wei Huang, Jonathan Toma, Jun Komano, Mikiro Yanaka, Yuetsu Tanaka, and Naoki Yamamoto	2940–2948
Detection and Quantification of Minor Human Immunodeficiency Virus Type 1 Variants Harboring K103N and Y181C Resistance Mutations in Subtype A and D Isolates by Allele-Specific Real-Time PCR	Andrea Hauser, Kizito Mugenyi, Rose Kabasinguzi, Kerstin Bluethgen, Claudia Kuecherer, Gundel Harms, and Andrea Kunz	2965–2973
Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir	N. Perrottet, C. Csajka, M. Pascual, O. Manuel, F. Lamothe, P. Meylan, J. D. Aubert, J. P. Venetz, P. Soccac, L. A. Decosterd, J. Biollaz, and T. Buclin	3017–3023
Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals	Walter Rangel Lopes de Campos, Dayaneethie Coopusamy, Lynn Morris, Bongani M. Mayosi, and Makobetsa Khati	3056–3064
Susceptibility of Highly Pathogenic H5N1 Influenza Viruses to the Neuraminidase Inhibitor Oseltamivir Differs In Vitro and in a Mouse Model	Elena A. Govorkova, Natalia A. Ilyushina, Jennifer L. McClaren, Tri S. P. Naipospos, Bounlom Douangngeun, and Robert G. Webster	3088–3096
Antiretroviral Drug Resistance Surveillance among Treatment-Naive Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance	Inês Bártole, Cheila Rocha, José Bartolomeu, António Gama, Marlene Fonseca, Ana Mendes, Filipa Cristina, Sven Thamm, Marta Epalanga, Patrícia Cavaco Silva, and Nuno Taveira	3156–3158

EXPERIMENTAL THERAPEUTICS

Piperaquine Pharmacodynamics and Parasite Viability in a Murine Malaria Model	Brioni R. Moore, Kenneth F. Ilett, Madhu Page-Sharp, Jeffrey D. Jago, and Kevin T. Batty	2707–2713
Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant <i>Staphylococcus aureus</i>: Importance of Combination with Rifampin	Anne-Kathrin John, Daniela Baldoni, Manuel Haschke, Katharina Rentsch, Patrick Schaerli, Werner Zimmerli, and Andrej Trampuz	2719–2724
Activity of Telavancin against <i>Staphylococcus aureus</i> Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations	Steven N. Leonard, Céline Vidaillac, and Michael J. Rybak	2928–2933
Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against <i>Mycobacterium ulcerans</i> in Mice	Baohong Ji, Aurélie Chauffour, Alexandra Aubry, Jérôme Robert, Murad Ibrahim, and Vincent Jarlier	2955–2959
Combination of Daptomycin plus Ceftriaxone Is More Active than Vancomycin plus Ceftriaxone in Experimental Meningitis after Addition of Dexamethasone	U. Egermann, Z. Stanga, A. Ramin, F. Acosta, A. Stucki, P. Gerber, M. Cottagnoud, and P. Cottagnoud	3030–3033
Eradication of Bacteria in Suspension and Biofilms Using Methylene Blue-Loaded Dynamic Nanoplatfoms	Jianfeng Wu, Hao Xu, Wei Tang, Raoul Kopelman, Martin A. Philbert, and Chuanwu Xi	3042–3048
An Engineered R-Type Pyocin Is a Highly Specific and Sensitive Bactericidal Agent for the Food-Borne Pathogen <i>Escherichia coli</i> O157:H7	Dean Scholl, Mike Cooley, Steve R. Williams, Dana Gebhart, David Martin, Anna Bates, and Robert Mandrell	3074–3080
Reduction of Amphotericin B-Induced Renal Tubular Apoptosis by <i>N</i>-Acetylcysteine	Z. Odabasi, A. Karaalp, H. Cermik, J. Mohr, E. T. Tigen, M. Koc, and V. Korten	3100–3102
Activity of SQ641, a Capuramycin Analog, in a Murine Model of Tuberculosis	Boris V. Nikonenko, Venkata M. Reddy, Marina Protopopova, Elena Bogatcheva, Leo Einck, and Carol A. Nacy	3138–3139
Comparison of Tigecycline and Vancomycin for Treatment of Experimental Foreign-Body Infection Due to Methicillin-Resistant <i>Staphylococcus aureus</i>	Pierre Vaudaux, Bénédicte Fleury, Aslan Gjinovci, Elzbieta Huggler, Manuela Tangomo-Bento, and Daniel P. Lew	3150–3152

CLINICAL THERAPEUTICS

Early- and Late-Onset Pneumonia: Is This Still a Useful Classification?	Petra Gastmeier, Dorit Sohr, Christine Geffers, Henning Rüden, Ralf-Peter Vonberg, and Tobias Welte	2714–2718
Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections	D. Krievins, R. Brandt, S. Hawser, P. Hadvary, and K. Islam	2834–2840
Prevalence and Risk Factors for Aminoglycoside Nephrotoxicity in Intensive Care Units	João F. P. Oliveira, Carolina A. Silva, Camila D. Barbieri, Giselle M. Oliveira, Dirce M. T. Zanetta, and Emmanuel A. Burdmann	2887–2891
Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis	Brad Spellberg, David Andes, Mario Perez, Anne Anglim, Hector Bonilla, Glenn E. Mathisen, Thomas J. Walsh, and Ashraf S. Ibrahim	3122–3125

PHARMACOLOGY

Effects of Cranberry Juice on Pharmacokinetics of β-Lactam Antibiotics following Oral Administration	Meng Li, Marilee A. Andrew, Joanne Wang, David H. Salinger, Paolo Vicini, Richard W. Grady, Brian Phillips, Danny D. Shen, and Gail D. Anderson	2725–2732
Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir	William D. Hanley, Larissa A. Wenning, Allison Moreau, James T. Kost, Eric Mangin, Trisha Shamp, Julie A. Stone, Keith M. Gottesdiener, John A. Wagner, and Marian Iwamoto	2752–2755
In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates	Anthony M. Nicasio, Jared L. Crandon, and David P. Nicolau	2756–2761
Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis	April Barbour, Stephan Schmidt, Sreedharan Nair Sabarinath, Maria Grant, Christoph Seubert, Donna Skee, Bindu Murthy, and Hartmut Derendorf	2773–2776
Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients	Salvador E. Cabrera, Dolores Santos, María P. Valverde, Alfonso Domínguez-Gil, Francisco González, Guillermo Luna, and María J. García	2791–2798
Comparison of the Pharmacodynamics of Biapenem in Bronchial Epithelial Lining Fluid in Healthy Volunteers Given Half-Hour and Three-Hour Intravenous Infusions	Eiki Kikuchi, Junko Kikuchi, Yasuyuki Nasuhara, Satoshi Oizumi, Akitoshi Ishizaka, and Masaharu Nishimura	2799–2803
Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir	Larissa A. Wenning, William D. Hanley, Diana M. Brainard, Amelia S. Petry, Kalyan Ghosh, Bo Jin, Eric Mangin, Thomas C. Marbury, Jolene K. Berg, Jeffrey A. Chodakewitz, Julie A. Stone, Keith M. Gottesdiener, John A. Wagner, and Marian Iwamoto	2852–2856
Renal Disposition of Colistin in the Isolated Perfused Rat Kidney	Zheng Ma, Jiping Wang, Roger L. Nation, Jian Li, John D. Turnidge, Kingsley Coulthard, and Robert W. Milne	2857–2864
Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates	Leonard E. Weisman, Helen M. Thackray, Joseph A. Garcia-Prats, Mirjana Nesin, Joseph H. Schneider, Jennifer Fretz, John F. Kokai-Kun, James J. Mond, William G. Kramer, and Gerald W. Fischer	2879–2886
Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral Administration	Khaled Abduljalil, Martina Kinzig, Jürgen Bulitta, Stefan Horkovics-Kovats, Fritz Sörgel, Michael Rodamer, and Uwe Fuhr	2892–2901
Data Mining Validation of Fluconazole Breakpoints Established by the European Committee on Antimicrobial Susceptibility Testing	Isabel Cuesta, Concha Bielza, Pedro Larrañaga, Manuel Cuenca-Estrella, Fernando Laguna, Dolores Rodríguez-Pardo, Benito Almirante, Albert Pahissa, and Juan L. Rodríguez-Tudela	2949–2954

Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy Volunteers	Elizabeth S. Dodds Ashley, Jay B. Varkey, Gopal Krishna, Donna Vickery, Lei Ma, Xin Yu, Darshana Malavade, Megan Goodwin, John R. Perfect, and Eddie Power	2960–2964
Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs	Sylvain Goutelle, Laurent Bourguignon, Pascal H. Maire, Michael Van Guilder, John E. Conte, Jr., and Roger W. Jelliffe	2974–2981
Pharmacological Exploitation of an Off-Target Antibacterial Effect of the Cyclooxygenase-2 Inhibitor Celecoxib against <i>Francisella tularensis</i>	Hao-Chieh Chiu, Jian Yang, Shilpa Soni, Samuel K. Kulp, John S. Gunn, Larry S. Schlesinger, and Ching-Shih Chen	2998–3002
In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model	D. Andes, W. Craig, L. A. Nielsen, and H. H. Kristensen	3003–3009
Integration of Pharmacokinetic and Pharmacodynamic Indices of Orbifloxacin in Beagle Dogs after a Single Intravenous and Intramuscular Administration	Elias Gebru, Joong-Su Lee, Zhi-Qiang Chang, Mi-Hyun Hwang, Henrique Cheng, and Seung-Chun Park	3024–3029
Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers	Martin Bitzan, Ruth Poole, Mariam Mehran, Eric Sicard, Catherine Brockus, Claire Thuning-Roberson, and Marc Rivière	3081–3087
In Vitro Elution of Daptomycin by a Synthetic Crystalline Semihydrate Form of Calcium Sulfate, Stimulan	Kyriaki Kanellakopoulou, Periklis Panagopoulos, Efthymia Giannitsioti, Thomas Tsaganos, Dionyssia-Pinelopi Carrer, Nicolas Efstathopoulos, and Evangelos J. Giamarellos-Bourboulis	3106–3107
Prospective Open-Label Study of the Administration of Two-Percent Voriconazole Eye Drops	Daoud Al-Badriyeh, Lok Leung, Trent Roydhouse, Robert Fullinfaw, Mark Daniell, Geoffrey E. Davies, Kay Stewart, and David C. M. Kong	3153–3155
LETTER TO THE EDITOR		
CMY-29 and CMY-30, Two Novel Plasmid-Mediated AmpC β-Lactamases	Christopher E. Pope, Philip E. Carter, and Helen M. Heffernan	3178
ERRATA		
Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever	Joseph S. Bubalo, Myrna Y. Munar, Ganesh Cherala, Brandon Hayes-Lattin, and Richard Maziarz	3179
Early Dissemination of KPC-2-Producing <i>Klebsiella pneumoniae</i> Strains in Brazil	Mónica Pavez, Elsa M. Mamizuka, and Nilton Lincopan	3180